Accessibility Menu
Drugs Made In America Acquisition II Corp. logo

Drugs Made In America Acquisition II Corp.(NASDAQ) DMIIU

Current Price$10.11
Market Cap$645.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+2%
5 YearN/A
1 YearN/A
1 Month+0%
Drugs Made In America Acquisition II Corp. last closing stock price
MetricPriceDate
Last closeUSD 10.142026-07-21
Drugs Made In America Acquisition II Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.2%USD 10.162026-07-13
1 month+0.2%USD 10.122026-06-15
3 month+0.6%USD 10.082026-04-22
Year to date+1.25%USD 10.022025-12-31
Since inception+1.5%USD 9.992025-09-25

Drugs Made In America Acquisition II Corp. Financials at a Glance

Market Cap

$645.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$8.58

EPS (TTM)

$0.13

P/E Ratio

75.67

Dividend

$0.00

Beta (Volatility)

-0.22 (Low)

Price

$10.11

Volume

0

Open

$10.11

Previous Close

$10.11

Daily Range

$10.11 - $10.11

52-Week Range

$9.94 - $10.80

Estimated Earnings Date

N/A

DMIIU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. Unit is a Special Purpose Acquisition Company (SPAC) focused on identifying and merging with businesses in the pharmaceutical and drug industries. The company aims to reduce the United States' reliance on international drug manufacturing through strategic acquisitions.

Products and Services
  • Investment units comprising one common stock share and a right
  • Focus on mergers and acquisitions in the pharmaceutical sector
  • Commitment to enhancing domestic drug production capabilities
Growth Outlook
  • Market cap of approximately $706.57 million indicates strong investor interest
  • Low beta of 0.059 suggests stability compared to the overall market
  • Recent stock price range between $9.935 and $10.8 reflects consistent valuation
Financial Highlights
  • Current stock price stands at $10.16, showing resilience
  • Volume averages around 1,706 shares, indicating active trading
  • No dividends paid, focusing on growth through acquisitions
Drugs Made In America Acquisition II Corp. Unit operates with a clear mission to enhance the domestic pharmaceutical landscape. The company's strategic focus on mergers and acquisitions positions it well within a critical industry, especially as the demand for locally produced drugs continues to rise. The financial metrics reflect a stable investment environment, with a solid market capitalization and consistent trading activity. Investors may find the company's commitment to reducing reliance on international drug manufacturing particularly appealing in today's economic climate.
AI Generated • Jul 3, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Lynn Darlene Stockwell

Headquarters

New York, NY 33301, US

DMIIU Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

3.49%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

1.32%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$645.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.70M

Volume

0

Avg. Volume

1.33K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Drugs Made In America Acquisition II Corp. Performance Analysis

Drugs Made In America Acquisition II Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Drugs Made In America Acquisition II Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.00N/A
20252025-12-31USD 0.07N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$645.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$329.19

N/A

Employees

2

N/A

Net Income

$4.34

-73.1%

EBITDA

-$0.13

+2.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$0.80

+210.3%

Total Debt

$0.45

+1.8%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.45

+1.8%

Return on Assets

3.37%

N/A

Return on Invested Capital

129.99%

N/A

Free Cash Flow

-$0.10

+10.2%

Operating Cash Flow

-$0.10

+10.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GAINGladstone Investment Corp.
$16.07-1.41%
NCDLNuveen Churchill Direct Lending Corp.
$12.25-2.00%
MSIFMSC Income Fund, Inc.
$10.90-1.00%
NEWTNewtekOne, Inc.
$14.45-1.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.09-0.26%
TAT&T
$22.82-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.23+0.06%
CLFCleveland-Cliffs
$11.18+0.18%

Questions About DMIIU

What is the current price of Drugs Made In America Acquisition II Corp.?

Drugs Made In America Acquisition II Corp. is trading at $10.11 per share.

What is the 52-week range for Drugs Made In America Acquisition II Corp.?

Over the past 52 weeks, Drugs Made In America Acquisition II Corp. has traded between $9.94 and $10.80.

How much debt does Drugs Made In America Acquisition II Corp. have?

As of the most recent reporting period, Drugs Made In America Acquisition II Corp. reported total debt of $450.00K.

How much cash does Drugs Made In America Acquisition II Corp. have on hand?

Drugs Made In America Acquisition II Corp. reported $347.72K in cash and cash equivalents in its most recent financial results.

What is Drugs Made In America Acquisition II Corp.’s dividend yield?

Drugs Made In America Acquisition II Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services